Wide Ranks

BPTH

Bio-Path Holdings, Inc.

0.7701

Top Statistics
Market Cap 3 M Forward PE -0.4968 Revenue Growth 0.00 %
Current Ratio 1.67 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.1450 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 4 M Total Cash Per Share 1.57 Total Debt 55000
Total Debt To Equity 4.26 Current Ratio 1.67 Book Value Per Share 0.7140
All Measures
Short Ratio 3.00 % Message Board Id finmb_37512626 Shares Short Prior Month 9632
Return On Equity -3.66 City Bellaire Uuid 487c045c-5873-31de-8241-9c7b0f1dc686
Previous Close 0.8040 First Trade Date Epoch Utc 1 B Book Value 0.7140
Beta 0.2220 Total Debt 55000 Volume 61565
Price To Book 1.08 Last Split Date 1 B Fifty Two Week Low 0.6100
Total Cash Per Share 1.57 Shares Short Previous Month Date 1 B Target Median Price 12.00
Max Age 86400 Recommendation Mean 2.00 Sand P52 Week Change 0.3133
Target Mean Price 12.00 Net Income To Common -11597000 Short Percent Of Float 0.0210
Implied Shares Outstanding 4 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 69210 Average Volume10days 69210 Total Cash 4 M
Next Fiscal Year End 1 B Held Percent Insiders 0.0004 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 0.8040
Target Low Price 12.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 0.9526
Open 0.8090 Free Cashflow -3872250 State TX
Dividend Yield 0.00 % Return On Assets -1.40 Time Zone Short Name EST
Trailing Eps -8.34 Day Low 0.7366 Address1 4710 Bellaire Boulevard
Shares Outstanding 4 M Price Hint 4 Target High Price 12.00
Website https://www.biopathholdings.com 52 Week Change -0.9313 Average Volume 1 M
Forward Eps -4.04 Recommendation Key buy Compensation As Of Epoch Date 1 B
Quick Ratio 133.10 % Last Split Factor 1:20 Regular Market Day High 0.8090
Is_sp_500 False Profit Margins 0.00 % Debt To Equity 4.26
Fifty Two Week High 12.40 Day High 0.8090 Shares Short 77764
Regular Market Open 0.8090 Industry Key biotechnology Earnings Growth 0.00 %
Revenue Growth 0.00 % Shares Percent Shares Out 0.0210 Operating Cashflow -8861000
Currency USD Time Zone Full Name America/New_York Market Cap 3 M
Is_nasdaq_100 False Zip 77401 Quote Type EQUITY
Industry Biotechnology Long Name Bio-Path Holdings, Inc. Regular Market Day Low 0.7366
Held Percent Institutions 0.0109 Current Price 0.7701 Address2 Suite 210
Enterprise To Ebitda 0.1450 Financial Currency USD Current Ratio 1.67
Industry Disp Biotechnology Number Of Analyst Opinions 1 Country United States
Float Shares 2 M Two Hundred Day Average 2.41 Enterprise Value -1877345
Forward PE -0.4968 Regular Market Volume 61565 Ebitda -12976000
Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States.

The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.

Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome.

It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML.

The company was founded in 2007 and is based in Bellaire, Texas.